The preliminary trial results for a possible treatment for COVID-19 seem to suggest a possible breakthrough for one United Kingdom company, according to multiple reports.
Synairgen PLC, a biotech company from Southampton, UK, issued a statement on its website that on Monday, July 20, the company had yielded positive results from SNG001, the treatment that featured inhalation of a protein called interferon beta.